Synthekine logo

Synthekine Inc.


Synthekine Stock

Founded in 2019, Synthekine utilizes the potential of cytokine therapeutics to develop selective immunotherapies designed to improve the treatments of cancer and inflammatory disease. Using insights on cytokine structure and function, the company engineers therapeutics designed to unlock the full efficacy potential of cytokines while avoiding their associated toxicities.

Management Team

Debanjan Ray CEO
Martin Oft, M.D. Chief Scientific Officer
Naiver Rizvi, M.D. Chief Medical Officer

Funding Information